{"id":2672,"date":"2020-05-29T18:33:06","date_gmt":"2020-05-29T18:33:06","guid":{"rendered":"https:\/\/mirm-pitt.net\/technologies\/?post_type=avada_portfolio&p=2672"},"modified":"2020-07-08T07:30:24","modified_gmt":"2020-07-08T07:30:24","slug":"oncolytic-hsv-vector-4","status":"publish","type":"avada_portfolio","link":"https:\/\/mirm-pitt.net\/technologies\/patents\/oncolytic-hsv-vector-4\/","title":{"rendered":"Oncolytic HSV Vector"},"content":{"rendered":"

Oncolytic HSV Vector<\/h2>\n

Recombinant Oncolytic Herpes Simplex Virus (oHSV), Comprising One Or More Copies Of Target Sequences For One Or More MicroRNAs (MirNAS)<\/p>\n<\/div>

<\/div><\/div><\/div>

Inventors:<\/strong> Joseph C. Glorioso III: Hiroaki Uchida: Justus Bernhard Cohen<\/p>\n

Patent Number:<\/strong> 15\/204,350<\/p>\n

\n
\n
\n

Abstract<\/h3>\n
\n
\n
The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.<\/div>\n<\/section>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<\/div>
<\/div>
<\/div>
<\/div>